Associated Papers
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.
Hulse M et al.
Cancer Research, 2026
Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.
Fernando TM et al.
Nature Communications, 2020
33144586 (PubMed )
Supplement: 41467_2020_19402_MOESM6_ESM.xlsx › Sheet1
SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma.
Kurashima K et al.
Nar Cancer, 2020
34316685 (PubMed )
Supplement: narcancer_2_2_zcaa005_s8.pdf
Elucidation of the functional roles of the Q and I motifs in the human chromatin-remodeling enzyme BRG1.
Hoffmeister H et al.
The Journal of Biological Chemistry, 2019
Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.
Testoni E et al.
Embo Molecular Medicine, 2016
26758680 (PubMed )
Supplement: EMMM-8-105-s006.xlsx › H2126_mutations_cBio
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
Fillmore CM et al.
Nature, 2015
25629630 (PubMed )
Supplement: NIHMS645459-supplement-1.pdf
Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors.
Rodriguez-Nieto S et al.
Human Mutation, 2011
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.
Medina PP et al.
Human Mutation, 2008
Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
Medina PP et al.
Epigenetics, 0
Select a paper to view details